Clemizole

Clemizole

SCHEMBL29938

Clc1ccc(Cn2c(CN3CCCC3)nc3ccccc32)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 2/20 1.00
TDP1 Q9NUW8 2/20 1.00
CYP1A2 P05177 2/20 1.00
CYP2D6 P10635 2/20 1.00
CYP2C9 P11712 2/20 1.00
CYP2C19 P33261 2/20 1.00
NR1I2 O75469 1/20 1.00
ABCB11 O95342 1/20 1.00
LMNA P02545 1/20 1.00
ESR1 P03372 1/20 1.00
PGR P06401 1/20 1.00
CYP3A4 P08684 1/20 1.00
PKM P14618 1/20 1.00
TSHR P16473 1/20 1.00
ADRA2B P18089 1/20 1.00
HTR2A P28223 1/20 1.00
ADRA1A P35348 1/20 1.00
HRH1 P35367 1/20 1.00
HTR2B P41595 1/20 1.00
SLC6A3 Q01959 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Clemizole SCHEMBL29403196 1.00 HIF1A (1.00) HIF1ATDP1CYP1A2CYP2D6CYP2C9
SCHEMBL13187056 0.99 HIF1A (0.97) HIF1ATDP1CYP1A2CYP2D6CYP2C9
Clemizole SCHEMBL31707402 0.99 HIF1A (1.00) HIF1ATDP1CYP1A2CYP2D6CYP2C9
Clemizole SCHEMBL19976072 0.99 HIF1A (0.97) HIF1ATDP1CYP1A2CYP2D6CYP2C9
Clemizole SCHEMBL19976068 0.99 HIF1A (0.97) HIF1ATDP1CYP1A2CYP2D6CYP2C9
Clemizole SCHEMBL210095 0.99 HIF1A (1.00) HIF1ATDP1CYP1A2CYP2D6CYP2C9
SCHEMBL13186938 0.99 HIF1A (0.97) HIF1ATDP1CYP1A2CYP2D6CYP2C9
Clemizole SCHEMBL19976085 0.94 HIF1A (0.88) HIF1ATDP1CYP1A2CYP2D6CYP2C9
Clemizole SCHEMBL9444743 0.93 HIF1A (0.86) HIF1ATDP1CYP1A2CYP2D6CYP2C9
Clemizole SCHEMBL19976078 0.93 HIF1A (0.86) HIF1ATDP1CYP1A2CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 4004 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4746863-A1 ENDOXIFEN COMPOSITIONS AND METHODS OF USE THEREOF AND SYNTHESIS THEREOF Atossa Therapeutics, Inc. (US) 2026-05-27 EP claimed
US-20260137654-A1 COMPOUNDS AND METHODS FOR TREATING AN EPILEPTIC DISORDER THE REGENTS OF THE UNIV OF CALIFORNIA (US) 2026-05-21 US claimed
WO-2026101937-A1 COMPOSITIONS COMPRISING (Z)-ENDOXIFEN AND A CDK4/6 INHIBITOR AND METHODS OF USE THEREOF ATOSSA THERAPEUTICS, INC. (US) 2026-05-15 WO claimed
US-20260083706-A1 5HT AGONISTS FOR TREATING DISORDERS UNIV CALIFORNIA (US) 2026-03-26 US claimed
EP-4043016-B1 THE 5HT AGONIST CLEMIZOLE FOR USE IN TREATING EPILEPSY DISORDERS UNIV CALIFORNIA (US) 2025-10-29 EP claimed
US-12447144-B2 5HT agonists for treating disorders THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-10-21 US claimed
US-12419866-B2 Compounds and methods for treating an epileptic disorder THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-09-23 US claimed
WO-2025151443-A1 ENDOXIFEN FOR TREATMENT OF RARE CANCERS ATOSSA THERAPEUTICS, INC. (US) 2025-07-17 WO claimed
WO-2025133679-A1 COMPOUNDS AND COMPOSITION FOR DNA PROTECTION ASSOCIAÇÃO PARA DESENVOLVIMENTO DO CENTRO ACADÉMICO DE INVESTIGAÇÃO E FORMAÇÃO BIOMÉDICA DO ALGARVE, AD-ABC (PT) 2025-06-26 WO claimed
WO-2025137145-A1 ORAL FORMULATIONS OF (Z)-ENDOXIFEN AND METHODS OF USE THEREOF ATOSSA THERAPEUTICS, INC. (US) 2025-06-26 WO claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
EP-0673782-B1 Recording sheets containing pyrrole, pyrrolidine, pyridine, piperidine, homopiperidine, quinoline, isoquinoline, quinuclidine, indole, and indazole compounds XEROX CORP (US) 2000-06-14 EP claimed
EP-0948359-A1 COMPOSITIONS CONTAINING LIPOPHILIC OLIGOSACCHARIDE ANTIBIOTIC AND ALBUMIN SCHERING CORPORATION (US) 1999-10-13 EP claimed
US-5776912-A Lipophilic oligosaccharide antibiotic compositions SCHERING CORPORATION (US) 1998-07-07 US claimed
WO-1998028011-A1 COMPOSITIONS CONTAINING LIPOPHILIC OLIGOSACCHARIDE ANTIBIOTIC AND ALBUMIN SCHERING CORPORATION (US) 1998-07-02 WO claimed
EP-0538011-B1 Lipophilic oligosaccharide antibiotic salt compositions SCHERING CORP (US) 1997-07-30 EP claimed
US-5624914-A EVERNINOMYCINS, CYCLODEXTRAN DERIVATIVE, NONIONIC SURFACTANT SCHERING CORPORATION (US) 1997-04-29 US claimed
EP-0610295-A1 LIPOPHILIC OLIGOSACCHARIDE ANTIBIOTIC SALT COMPOSITIONS SCHERING CORPORATION (US) 1994-08-17 EP claimed
WO-1993007904-A1 LIPOPHILIC OLIGOSACCHARIDE ANTIBIOTIC SALT COMPOSITIONS SCHERING CORPORATION (US) 1993-04-29 WO claimed
EP-0538011-A1 Lipophilic oligosaccharide antibiotic salt compositions SCHERING CORPORATION (US) 1993-04-21 EP claimed